ArticleJournal for immunotherapy of cancer2021
Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy.
Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02403089 (Ontogeny of MAIT Cells in Neonates and Hematopoietic Stem Cell Transplant Recipients), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ontogeny of MAIT Cells in Neonates and Hematopoietic Stem Cell Transplant Recipients
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Immune checkpoint expression in mucosal-associated invariant T cells is stimulus-dependent.Journal of leukocyte biology · 2025Pooled it
- Immune features of graft-derived mucosal-associated invariant T cells predict gastrointestinal graft-versus-host disease.British journal of haematology · 2026Article
- Avoidance of MAIT cells is an essential determinant ofProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Dual Roles of MAIT Cells in the Tumor Microenvironment: Implications for Cancer Immunity and Therapy.Immune network · 2026Review
- Estrogen Induced Regulation of Mucosal-Associated Invariant T Cells in Asthma.Journal of immunology research · 2026Article
- Breakthrough for Anticancer Immunotherapy: Current Advances in Manufacturing Protocols of Chimeric Antigen Receptor-Based Therapies.Antibodies (Basel, Switzerland) · 2025Review
- Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.Methods and protocols · 2025Review
- Interplay between innate-like T-cells and microRNAs in cancer immunity.Discover oncology · 2025Review
- Understanding Liver Transplantation Outcomes Through the Lens of Its Tissue-resident Immunobiome.Transplantation · 2025Review
- Review
- Are monocytes a preferable option to develop myeloid cell-based therapies for solid tumors?Journal of experimental & clinical cancer research : CR · 2025Review
- Article
- Mucosal-associated invariant T cells modulate innate immune cells and inhibit colon cancer growth.Scandinavian journal of immunology · 2024Article
- MAIT Cells Modulate Innate Immune Cells and Inhibit Colon Cancer Growth.bioRxiv : the preprint server for biology · 2024Article
- Human MAIT cells inhibit alloreactive T cell responses and protect against acute graft-versus-host disease.JCI insight · 2024Article
- Review
- Insights into the tissue repair features of MAIT cells.Frontiers in immunology · 2024Review
- Mucosal-associated invariant T cells in cancer: dual roles, complex interactions and therapeutic potential.Frontiers in immunology · 2024Review
- CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy.Frontiers in immunology · 2024Review
- Innate lymphoid cells and innate-like T cells in cancer - at the crossroads of innate and adaptive immunity.Nature reviews. Cancer · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMucosal-associated invariant T (MAIT) cells are semi-invariant T cells that recognize microbial antigens presented by the highly conserved MR1 molecule. MAIT cells are predominantly localized in the liver and barrier tissues and are potent effectors of antimicrobial defense. MAIT cells are very few at birth and accumulate gradually over a period of about 6 years during the infancy. The cytotoxic potential of MAIT cells, as well as their newly described regulatory and tissue repair functions, open the possibility of exploiting their properties in adoptive therapy. A prerequisite for their use as 'universal' cells would be a lack of alloreactive potential, which remains to be demonstrated.
methodsWe used ex vivo, in vitro and in vivo models to determine if human MAIT cells contribute to allogeneic responses.
resultsWe show that recovery of MAIT cells after allogeneic hematopoietic stem cell transplantation recapitulates their slow physiological expansion in early childhood, independent of recovery of non-MAIT T cells. In vitro, signals provided by allogeneic cells and cytokines do not induce sustained MAIT cell proliferation. In vivo, human MAIT cells do not expand nor accumulate in tissues in a model of T-cell-mediated xenogeneic graft-versus-host disease in immunodeficient mice.
conclusionsAltogether, these results provide evidence that MAIT cells are devoid of alloreactive potential and pave the way for harnessing their translational potential in universal adoptive therapy overcoming barriers of HLA disparity. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov number NCT02403089.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.